There are an increasing number of advanced therapies for ulcerative colitis on the market and in the development pipeline. But with the notable exception of results from the VARSITY trial comparing vedolizumab and adalimumab, there are no direct head-to-head randomised controlled trials of the efficacy and safety of the newer therapies. Can clinicians therefore look ...
Do we need head-to-head trials to make treatment decisions in ulcerative colitis?
20 Mar 2019
Sponsored by Takeda Pharmaceuticals Australia Pty Ltd